胰高血糖素样肽-1受体激动剂与心力衰竭:需进一步证据生成与实践指南优化
全球2型糖尿病和心力衰竭的发病率与患病率均呈恶化趋势,需优化共病患者防治策略。现有指南推荐GLP-1受体激动剂和SGLT2抑制剂作为高动脉粥样硬化性心血管疾病风险患者生活方式干预的附加治疗,但对心衰预防与治疗、不同心衰表型未加区分。GLP-1受体激动剂在心衰相关结局方面缺乏明确获益证据,甚至射血分数降低心衰患者的安全性存疑,需专门试验评估其疗效与安全性。
要点
- 指南推荐GLP-1受体激动剂用于高ASCVD风险的T2DM患者,但对心衰未明确区分预防与治疗。
- GLP-1受体激动剂对心衰相关结局无明确获益,HFrEF患者安全性不确定。
- 需专门开展HFrEF和HFpEF合并T2DM患者的试验以评估GLP-1受体激动剂。
核心结论
- GLP-1受体激动剂在心力衰竭患者中的证据不足,当前指南推荐需优化。
- 需专门试验评估GLP-1受体激动剂在HFrEF和HFpEF合并T2DM患者中的疗效、安全性和风险获益。
研究设计与样本
- 本文为Circulation发表的指南类文章,讨论GLP-1受体激动剂与心力衰竭的证据现状及指南推荐。
主要发现
- 多项指南和共识推荐GLP-1受体激动剂和SGLT2抑制剂作为高ASCVD风险患者生活方式干预的附加治疗。
- 这些推荐对心衰未提及或未区分心衰预防与已确诊心衰的治疗,也未区分不同心衰表型。
- 随机试验的机制见解和观察提示GLP-1受体激动剂对心衰相关结局无明确获益,HFrEF患者安全性不确定。
- 理论依据提示GLP-1受体激动剂可能使HFpEF患者获益。
关键数值与推荐
- 指南推荐GLP-1受体激动剂和SGLT2抑制剂作为高ASCVD风险患者生活方式干预(联合或不联合二甲双胍)的附加治疗。
- 部分新声明建议GLP-1受体激动剂用于T2DM合并ASCVD患者,也用于已确诊心衰患者,但后者缺乏证据。
临床怎么用
- GLP-1受体激动剂可能适用于有心衰风险的患者,但对已确诊心衰尤其HFrEF患者需谨慎评估。
- 临床应区分心衰预防与治疗以及不同心衰表型来使用GLP-1受体激动剂。
局限性
- 缺乏GLP-1受体激动剂在HFrEF和HFpEF合并T2DM患者中的专门试验证据。
- 现有指南推荐未区分心衰预防与治疗及不同心衰表型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With worsening epidemiological trends for both the incidence and prevalence of type 2 diabetes mellitus (T2DM) and heart failure (HF) worldwide, it is critical to implement optimal prevention and treatment strategies for patients with these comorbidities, either alone or concomitantly. Several guidelines and consensus statements have recommended glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter type 2 inhibitors as add-ons to lifestyle interventions with or without metformin in those at high atherosclerotic cardiovascular disease risk. However, these recommendations are either silent about HF or fail to differentiate between the prevention of HF in those at risk versus the treatment of individuals with manifest HF. Furthermore, these documents do not differentiate among those with different HF phenotypes. This distinction, even though important, may not be critical for sodium-glucose cotransporter type 2 inhibitors in view of the consistent data for benefit for both atherosclerotic cardiovascular disease- and HF-related outcomes that have emerged from the regulatory-mandated cardiovascular outcome trials for all sodium-glucose cotransporter type 2 inhibitors and the recent DAPA-HF trial (Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction)demonstrating the benefit of dapagliflozin on HF-related outcomes in patients with HF with reduced ejection fraction with or without T2DM. However, the distinction may be crucial for glucagon-like peptide-1 receptor agonists and other antihyperglycemic agents. Indeed, in several of the new statements, glucagon-like peptide-1 receptor agonists are suggested treatment not only for patients with T2DM and atherosclerotic cardiovascular disease, but also in those with manifest HF, despite a lack of evidence for the latter recommendation. Although glucagon-like peptide-1 receptor agonists may be appropriate to use in patients at risk for HF, mechanistic insights and observations from randomized trials suggest no clear benefit on HF-related outcomes and even uncertainty regarding the safety in those with HF with reduced ejection fraction. Conversely, theoretical rationales suggest that these agents may benefit patients with HF with preserved ejection fraction. Considering that millions of patients with T2DM have HF, these concerns have public health implications that necessitate the thoughtful use of these therapies. Achieving this aim will require dedicated trials with these drugs in both patients who have HF with reduced ejection fraction and HF with preserved ejection fraction with T2DM to assess their efficacy, safety, and risk-benefit profile.
引用
- Khan MS, Fonarow GC, McGuire DK, et al. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation. 2020. PMID: 32955939. doi:10.1161/CIRCULATIONAHA.120.045888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。